Table 1.

Robotic Kidney Transplant and Control Patient Characteristics

	Robotic Transplant (n=28)	Controls (n=28)	P value
Demographics
Age (years), mean (SD)	47.9 (10.7)	49.8 (10.8)	0.51
Gender (male), No. (%)	13 (46.4)	11 (39.3)	0.59
Race (African American/Hispanic/White), No. (%)	13/10/5 (46.4/35.7/17.9)	13/10/5 (46.4/35.7/17.9)
Clinical
BMI (kg/m2), mean (SD)	42.6 (7.8)	38.1 (5.4)	0.02
Obese (30≤BMI<35)/Morbidly Obese (BMI≥35), No. (%)	6/22 (21.4/78.6)	6/22 (21.4/78.6)
Creatinine pre-transplant (mg/dl), mean (SD)	7.6 (3.5)	6.3 (2.5)	0.11
Dialysis, No. (%)	19 (67.9)	20 (71.4)	0.77
Duration on dialysis (months; n=17/17), mean (SD)	32.0 (34.7)	15.6 (11.8)	0.08
Crossmatch positive, No. (%)	7 (25.0)	7 (25.0)
ABO incompatible, No. (%)	1 (3.6)	1 (3.6)
Co-morbidities
CAD, No. (%)	9 (32.1)	9 (32.1)
CVD, No. (%)	1 (3.6)	4 (14.3)	0.35
PAV, No. (%)	2 (7.1)	4 (14.3)	0.67
Asthma/sleep apnea, No. (%)	5 (17.9)	3 (10.7)	0.71
Congestive heart failure, No. (%)	2 (7.1)	2 (7.1)
Cause of Kidney Failure
Diabetes, No. (%)	7 (25.0)	2 (7.1)	0.14
Hypertension, No. (%)	8 (28.6)	11 (39.3)	0.40
Diabetes + Hypertension, No. (%)	2 (7.1)	10 (35.7)	0.009
FSGS, No. (%)	2 (7.1)	1 (3.6)	0.99
Graft failure/re-transplant, No. (%)	2 (7.1)	0	0.49
Lupus nephritis, No. (%)	1 (3.6)	0	0.99
Obstructive uropathy, No. (%)	1 (3.6)	0	0.99
Analgesic nephropathy, No. (%)	1 (3.6)	0	0.99
Wegener's granulomatis, No. (%)	1 (3.6)	0	0.99
Post-infectious crescentic glomerulonephritis, No. (%)	1 (3.6)	0	0.99
Alport's syndrome, No. (%)	0	1 (3.6)	0.99
Hemolytic uremic syndrome, No. (%)	0	1 (3.6)	0.99
Hypertension + nephrotic syndrome, No. (%)	0	1 (3.6)	0.99
Unknown, No. (%)	2 (7.1)	1 (3.6)	0.99

SD, standard deviation; BMI, body mass index; CAD, coronary artery disease; CVD, cerebrovascular disease; PAV, peripheral arterial disease; FSGS, focal segmental glomerulosclerosis

To convert creatinine (mg/dl) to SI units (umol/L), multiply by 88.4